On Jan. 13, 2026, HMP posted the second of a 3-part interview on the Viewpoints section of “Wounds” (HMP Global Learning Network). This segment is about “How CTP Regulatory Changes Could Impact Wound Type and Subpopulations.”
The video link also includes the full transcript and a summary. One of the questions was whether specific wound types or populations would be affected.
One key takeaway was that the flat product price is independent of wound type; wound-type rules apply via LCDs/WISeR, not pricing. Clinicians must select products costing <~$127/cm² to avoid losses. Although I did not say it in the interview, physicians actually need to select products that cost less than $90 because they must account for potential losses from the 20% “patient portion”, the 2% across the board sequester on all physician payment, and the wage index adjustment.
The biggest potentially negative impact would be on “mobile” care, particularly in the home.
Thank you, HMP!
Related information:
- CMS Prepares to Launch a Prior Authorization Model for “Skin Substitutes” in Traditional Medicare as Part of the WISeR Initiative – Caroline Fife M.D.
- A New Era for Cellular Tissue Products / Skin Substitutes – Caroline Fife M.D.
The post Part Two of My Interview on CTP Payment Changes on HMP Global Learning Network/Wounds appeared first on Caroline Fife M.D..